ClinicalTrials.gg
RecruitingNCT06796062Updated Jan 23, 2026

Psilocybin for Opioid Use Disorder (OUD)

A Phase 2 interventional study of Psilocybin in Opioid Use Disorder, sponsored by NYU Langone Health. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by NYU Langone Health · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Opioid-Related Disorders by NYU Langone Health — 4 open to participants now, 5 under way, 1 of them phase 3. Opioid-Related Disorders · NYU Langone Health.

Planned enrollment
5th of 19
480 · median 217
Started
2025
with 1 other
Phase 2
3 of 23
2 open now
Registered
23rd of 23
by date

Among the 23 studies in Opioid-Related Disorders by NYU Langone Health, this one is the 5th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 2, and was the 23rd registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

4 of the 23 studies in Opioid-Related Disorders by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Opioid-Related Disorders by NYU Langone Health, or all of them as a file.
02

Study summary

This is a double-blind, adaptive, 2-stage, multi-site, phase 2 randomized controlled clinical trial designed to evaluate effects of moderate and high dose psilocybin, relative to low-dose psilocybin control, in OUD patients who continue to use illicit opioids in spite of adherence to standard-of-care treatment with methadone. Up to 480 participations will be consented to yield 240 randomized participants. This study is part of the NIH HEAL Initiative (https://heal.nih.gov/).

In Stage 1, subjects will be randomly assigned to one of three groups: psilocybin 30 mg (high dose), psilocybin 20 mg (medium dose), and psilocybin 1 mg (control condition). By the end of Stage 1, an interim statistical analysis will be performed. The study will proceed to Stage 2 if at least one of the active dosages of psilocybin demonstrates 1) acceptable safety, based on analysis of safety data from Stage 1; and 2) conditional power of at least 25%, based on effect size estimates for the primary opioid use outcome (weeks of biologically-verified abstinence during 24 weeks of follow-up). Using a priori decision rules, the interim analysis will determine which of the active treatment groups (30 mg, 20 mg, or both) will be retained in Stage 2 of the trial. Stage 2 will continue the study, using the same treatment and assessment protocols, but retaining only the active dosage or dosages with a high probability of demonstrating efficacy relative to the psilocybin 1 mg control condition.

The primary aims are to 1) Evaluate safety and efficacy outcomes in Stage 1 subjects in order to optimize design of the Stage 2, 2) Determine whether treatment with a single high (30 mg) or medium (20 mg) dose of psilocybin improves OUD treatment outcomes, relative to psilocybin 1 mg (control condition), in patients who continue to use illicit opioids despite adherence to methadone treatment, 3) Evaluate the effects of high-dose psilocybin and medium dose psilocybin on self-reported OUD-related neuropsychopathology, and 4) Identify likely responders to psilocybin treatment by using machine learning to model post-treatment OUD outcomes, based on pretreatment characteristics including all relevant clinical data, evaluations, and questionnaires.

03

Conditions studied

  • Opioid Use Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are able to provide voluntary .
  2. Have a breath alcohol concentration ≤ 0.01% at Screening Part 2, as determined by a breath alcohol reading from a calibrated breath alcohol sensor. (Note: this criterion may be re-evaluated within the 30-day screening period. This criterion will also be reassessed at Baseline and on Day 0 (prior to IP administration). Those not meeting the criterion may be rescheduled once within 14 days if the criterion is likely to resolve within 14 days in the judgement of the Investigator).
  3. Are able to read, speak, and understand English, as documented during the informed consent process.

    a. Non-English speaking subjects will be excluded because the study is using only validated English-language versions of of assessment instruments.

  4. Are 18 to 65 years old, inclusive, at Screening Part 2.
  5. Have - Fifth Edition (DSM 5) diagnosis of OUD, based on an evaluation performed by trained study staff using the Mini-International Neuropsychiatric Interview (MINI).
  6. Want to stop their use of illicit opioids.
  7. Are in treatment at one of participating Opioid Treatment Programs (OTPs) for at least 6 months at the time of Screening Part 2.
  8. Are currently prescribed a methadone dose of at least 60 mg per day.
  9. Methadone dosage has changed by no more than 20 mg in the past month
  10. Have taken methadone at least 25 out of the last 30 days
  11. Have had at least one urine drug screen positive for non-prescribed opioids in the past 30 days at the time of Screening Part 2
  12. Report using opioids by insufflation, injection, or smoking
  13. Are able and willing to adhere to all study requirements, including attending all study visits and treatment sessions, and completing all assessments.
  14. Are able to provide at least one drug screen negative for illicit opioids, cocaine, and amphetamine-type stimulants during the screening period. (Note: this criterion may be re-evaluated within the 30-day screening period. This criterion will be reassessed at Day 0 [prior to IP administration]. Those not meeting the criterion on Day 0 may be rescheduled within 14 days if the criterion is likely to resolve in the judgement of the Investigator.)
  15. Agree to refrain from any non-prescribed psychotropic substance or illicit drug use for at least 72 hours prior to IP administration, with the exceptions of alcohol, cannabis, nicotine, and caffeine. Regarding alcohol and cannabis, subjects must agree to attempt to abstain at least 24 hours before the IP administration session. Regarding nicotine, they must agree not to use nicotine for at least 1 hour before and 6 hours following IP administration. Regarding caffeine, they must agree to consume approximately their usual amount of caffeine on the morning of Day 0 (prior to IP administration).
  16. Agree to refrain from taking all non-prescription medications and supplements (nutritional and herbal) for at least 1 week prior to the IP administration session unless approved by the Investigator.
  17. Are able to swallow capsules.
  18. Agree to practice effective as described below.

    1. Subjects are considered able to become pregnant unless they:

      • Do not have a uterus
      • Are (has had 12 months of natural amenorrhea with a matching clinical profile [age, history of vasomotor symptoms]) prior to Screening Part 2, or
      • Are surgically sterile (documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy)
    2. Subjects who are able to become pregnant must:

      • Have a negative pregnancy test at Screening Part 2 (Reassessed at Day 0 (pre-IP administration);
      • Not be currently breastfeeding;
      • Not intend to become pregnant during participation in this study;
      • Agree to use a highly effective form of contraception from the time of the Screening Part 2 until 7 days after the IP Administration Session. Highly effective forms of contraception include: 1) Consistent and correct usage of established oral contraception; 2) Injected or implanted hormonal methods of contraception; 3) Established intrauterine device or intrauterine system; 4) Bilateral tubal ligation; 5) Intercourse with a partner who has undergone effective surgical sterilization, provided that partner is the sole sexual partner of the study subject; 6) Abstinence from penile/vaginal intercourse, if the Investigator determines that the subject can reliably adhere to the plan, based on evaluation of the social circumstances of the subject.
    3. Agree not to donate or bank eggs from the time of Screening Part 2 until 7 days after the IP Administration Session.
    4. Subjects who can emit sperm are defined as those who:

      • Have one or more testes and
      • Have not had a documented effective surgical sterilization procedure (e.g., vasectomy, radical prostatectomy).
    5. Subjects who can emit sperm must:

      • Practice effective contraception from Screening Part 2 until 7 days after the IP Administration Session. Effective means forms of contraception include:
      • use condoms with spermicide if engaging in penile/vaginal intercourse;
      • abstain from penile/vaginal intercourse, if the Investigator determines that the subject can reliably adhere to the plan, based on evaluation of the social circumstances of the subject
      • Agree not to donate or bank sperm from the time of the Screening Part 2 until 7 days after the IP Administration Session
  19. Have a family member or friend who can assist with transportation and activities of daily living after the IP Administration Session, as determined by self-report at Screening Part 2 and confirmed by direct communication between a member of the clinical support team and the support person prior to randomization. (Note: this criterion will be reassessed on Day 0.
  20. Are able to provide adequate locator information. This criterion may be re-evaluated within the 30-day screening period.

Exclusion criteria

Exclusion Criteria:

  1. Have any medical condition that would preclude safe participation in the study, including the following, as determined by medical history review, physical examination, (ECG), and clinical laboratory tests:

    1. Seizure disorder
    2. Significantly impaired liver function, defined as 1) (ALT) and/or aspartate aminotransferase (AST) > 5 × (ULN); 2) ALT or AST > 3 × ULN with concomitant total > 2.0 × ULN; or 3) ALT or AST ≥ 3 × ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia.
    3. Cardiovascular disease including coronary artery disease, angina, history of arrhythmia (unless a successful ablation has been performed), heart failure, history of heart valve replacement, and history of cerebrovascular accident or .
    4. Uncontrolled hypertension with systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg. (Note: subjects who otherwise qualify at Screening Part 2 will have 3 opportunities to produce 1 blood pressure reading ≤ 140/90 mmHg (each reading will be collected at least 15 minutes apart). If blood pressure is consistently elevated > 140/90 mmHg across all 3 attempts, subjects may be referred to their primary care provider for management of hypertension. Upon management of blood pressure, subjects will have an opportunity to return once within the 30 day screening window to make 3 additional attempts at a blood pressure reading ≤ 140/90 mmHg. Subjects will be considered eligible upon registering 1 blood pressure reading ≤ 140/90 mmHg during the screening period. Blood pressure will be reassessed on Day 0 prior to dosing, and must be less than or equal to 140 systolic, 90 diastolic, with resting pulse ≤ 100 (ascertained within 20 minutes of drug administration in order for the participant to receive study medication.)
    5. Serious ECG abnormalities present on the ECG obtained on Day -65 (e.g., evidence of ischemia, myocardial infarction, corrected for heart rate [QTc] prolongation (QTc > 0.45 seconds), arrhythmia, or conduction abnormalities that increase the risk of arrhythmia.
    6. Hyperthyroidism
    7. Insulin-dependent diabetes
    8. Any other medical condition which precludes safe participation in the study in the medical opinion of the Investigator.

    (Note: medical history will be updated and ECG will be repeated on Day 0, prior to dosing. Those not meeting the criterion will not be randomized but may be rescheduled once within 14 days if the criterion is likely to resolve within 14 days in the judgement of the Investigator.)

  2. Have any of the following psychiatric disorders, as determined by the MINI, Psychiatric History and Psychosis Screening Questionnaire at Screening Part 2: (Note: psychiatric history will be re-evaluated on Day 0, but the MINI will not be re-administered on Day 0)

    1. Lifetime history of schizophrenia spectrum or other psychotic disorder.
    2. Lifetime history of bipolar disorder.
    3. Current severe major depression (based on a MINI diagnosis of major depression, current, and a MADRS score >34 at Screening)
    4. Alcohol use disorder including alcohol withdrawal.
    5. More than mild opioid withdrawal (COWS score >12). (This criterion may be re-evaluated within the 30-day screening period. This criterion will be reassessed on Day 0. Those not meeting the criterion may be rescheduled once within 14 days if the criterion is likely to resolve within 14 days in the judgement of the Investigator.)
  3. Have active suicidal ideation with intent, based on Columbia - Suicide Severity Rating Scale (C-SSRS) assessment (severity score >3) at Screening Part 2, confirmed by the Investigator. (Note: this criterion will be reassessed at each visit that occurs prior to Day 0, and on Day 0 prior to IP administration. Subjects will be discharged if actively suicidal, and appropriate follow-up will be arranged.arranged.
  4. Have made a suicide attempt within the past 12 months, based on C-SSRS assessment at Screening Part 2 and confirmation by the Investigator. (Note: this criterion will be reassessed at each visit that occurs prior to Day 0, and on Day 0 prior to IP administration. Subjects will be discharged if actively suicidal, and appropriate follow-up will be arranged.
  5. Have a family history (first degree relatives) of schizophrenia, schizoaffective disorder, or bipolar disorder type 1.
  6. Have a history of hallucinogen use disorder or hallucinogen persisting perception disorder (HPPD).
  7. Have any hallucinogen use in the past 1 year.
  8. Have > 25 lifetime uses of classic psychedelics.
  9. Are currently in jail, prison, or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities.
  10. Are taking any protocol-prohibited medications and supplements (See Section 6.5.3). Any prohibited medications and supplements must have been stopped for at least 5 elimination half-lives or 14 days, whichever is longer, prior to Day 0. Prescribed psychotropic medications and any other medically necessary medications must not be stopped in order to qualify for the study. (Note: concomitant medications will be reassessed on Day 0.)
  11. Have a known allergy or to psilocybin or any of the materials contained in the IP used in the study.
  12. Have an allergy, hypersensitivity, or other that would preclude safe treatment of acute hypertension, anxiety, or psychotic symptoms if necessary during or immediately after the IP Administration Session, using the adjunctive medications used in this study to treat these symptoms (i.e., unable to take captopril and unable to take clonidine; unable to take diazepam and unable to take lorazepam; or unable to take olanzapine).
  13. Have any other medical, psychiatric, or psychosocial disorder, symptom, condition, or situation that is likely to interfere with the establishment of rapport, adherence to study requirements, or safe administration of psilocybin, based on the judgement of the Investigator. (Note: This criterion will be reassessed on Day 0. Those not meeting the criterion will not be randomized but may be rescheduled once within 14 days if the criterion is likely to resolve within 14 days in the judgement of the Investigator.)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
480 participants (estimated)

Study arms

  • Experimental
    Stage 1: Psilocybin 30 mg (high dose)

    Participants will receive a single IP administration (30 mg) session and remain under supervision at the facility for 8 hours.

    Drug: Psilocybin

  • Experimental
    Stage 1: Psilocybin 20 mg (medium dose)

    Participants will receive a single IP administration (20 mg) session and remain under supervision at the facility for 8 hours.

    Drug: Psilocybin

  • Active comparator
    Psilocybin 1 mg (control)

    Participants will receive a single IP administration (1 mg) session and remain under supervision at the facility for 8 hours.

    Drug: Psilocybin

  • Experimental
    Stage 2: Psilocybin 30 mg (high dose)

    Participants will receive a single IP administration (30 mg) session and remain under supervision at the facility for 8 hours.

    Drug: Psilocybin

  • Experimental
    Stage 2: Psilocybin 20 mg (medium dose)

    Participants will receive a single IP administration (20 mg) session and remain under supervision at the facility for 8 hours.

    Drug: Psilocybin

Interventions

  • One capsule (1 mg, 20 mg, or 30 mg) administered once orally

06

What researchers measure

Primary outcomes

  1. Stage 1: The number of weeks during the 24 week follow-up period with no illicit opioid use

    Subject reports no illicit opioid use and provides a urine drug screen (UDS) negative for all classes of opioids other than methadone or other legally prescribed opioids.

    Time frame: Up to 24 weeks

  2. Stage 1: Number of adverse events

    Time frame: Up to 24 weeks

  3. Stage 1: Change in QTc during drug administration session

    Time frame: Up to 24 weeks

  4. Stage 2: The number of weeks during the 24 week follow-up period with no illicit opioid use

    Time frame: Up to 24 weeks

  5. Stage 2: Number of adverse events

    Time frame: Up to 24 weeks

  6. Stage 2: Change in QTc during drug administration session

    Time frame: Up to 24 weeks

  7. Stage 2: Total score on the Penn Craving Scale for Opioids

    The Penn Alcohol Craving Scale (PACS) is a 5-item questionnaire that measures an individual's craving to drink alcohol in the past week. The self-report measure includes questions about the frequency, intensity, and duration of craving, the ability to resist drinking, and asks for an overall rating of craving for alcohol for the previous week. Each question is scaled from 0 to 6. Low score (below 15) indicates minimal to no reported alcohol craving. Moderate score (15-20) suggests a moderate level of alcohol craving. High score (above 20) represents a high level of alcohol craving, potentially warranting further assessment and treatment

    Time frame: Up to 24 weeks

  8. Stage 2: Score on the Negative Affect subscale of the Positive and Negative Affect Scale

    The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire that consists of two 10-item scales to measure both positive and negative affect. Each item is rated on a 5-point verbal frequency scale of 1 (not at all) to 5 (very much). Scores range from 10 - 50 for both sets of items. For the total negative score, a lower score indicates less of a negative affect.

    Time frame: Up to 24 weeks

  9. Stage 2: Total score on the 20-item version of the Short Urgency, Premeditation, Perseverance, Sensation seeking, and Positive urgency (UPPS-P) Impulsive Behavior Scale (SUPPS-P)

    The 20-item version of the UPPS-P Impulsive Behavior Scale, also known as the SUPPS-P, is a shortened questionnaire that assesses five different dimensions of impulsivity: negative urgency, positive urgency, lack of perseverance, lack of premeditation, and sensation seeking; with four items dedicated to each dimension, totaling 20 questions in total. Responses are rated on a Likert scale (e.g., strongly disagree to strongly agree), with higher scores generally indicating a greater tendency towards impulsive behavior.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Stage 2: Time to opioid relapse

    Defined as the number of days from the day of investigational product (IP) administration to a day of opioid use which marked the start of a) 4 consecutive opioid use weeks or b) the start of 7 consecutive days of self-reported opioid use days (ranging from 0 to 168 days).

    Time frame: Up to 24 weeks

  2. Stage 2: Time to first illicit opioid use

    Time frame: Up to 24 weeks

07

Study locations

5 of 5 sites recruiting
  • Duke City Recovery Toolbox
    Albuquerque, New Mexico 87102, United States
    Recruiting
  • University of New Mexico
    Albuquerque, New Mexico 87106, United States
    Recruiting
  • StartCare
    Brooklyn, New York 11206, United States
    Recruiting
  • NYU Langone Health
    New York, New York 10016, United States
    Recruiting
  • VIP Community Services, Inc
    The Bronx, New York 10457, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request immediately following publication, no end date, provided the investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. The NDA provides basic descriptive and aggregate summary information for general public use. Such summary information may include summary counts and general statistics on completed assessment instruments. Access to subject level datasets submitted and stored in the NDA will only be provided for research purposes through the completion of the NDA Data Use Certification: OMB Control Number: 0925-0667. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Immediately following publication. No end date.

Access criteria: Access to subject level datasets submitted and stored in the The National Institute of Mental Health (NIMH) Data Archive (NDA) will only be provided for research purposes through the completion of the NDA Data Use Certification: Office of Management and Budget (OMB) Control Number: 0925-0667. For the majority of the data available in the NDA, Data Use Certifications will only be accepted from researchers who are sponsored by an institution registered in the NIH's Electronic Research Administration (eRA) Commons with an active Federal-wide Assurance issued through the Office for Human Research Protections (OHRP). Additionally, the application must include a reason for access related to scientific investigation, scholarship or teaching, or other form of research. A Data Access Committee (DAC) composed of NIH staff with relevant expertise reviews the Data Use Certification and makes decisions about whether to grant access to subject level data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Feb 2029, 38 months after the start.

Of 61 non-industry phase 2 interventional studies under Opioid-Related Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 38 months is close to that.

Counting every sponsor, half of 68 studies reached it within 40 months; a quarter within 23 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Jan 28, 2025
StartActual
Dec 17, 2025
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2029
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06796062
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Jan 28, 2025
Start date
Dec 17, 2025
Primary completion
Feb 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
Jan 23, 2026

Study contacts

Michael Bogenschutz, MD
Contact
Michael.bogenschutz@nyulangone.org
646-501-4026
Michael Bogenschutz, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion